TI
ALNY icon

Telemetry Investments’s Alnylam Pharmaceuticals ALNY Stock Holding History

Telemetry Investments’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-10,000
Closed -$875K – 138
2018
Q3 		$875K Buy
10,000
+5,000
+100% +$503K 0.4% 39
2018
Q2 		$492K Buy
+5,000
New +$496K 0.19% 61

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Telemetry Investments's ALNY Position: Q2 2018 in Review

Telemetry Investments sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2018, closing a stake of 2,500 shares — an estimated $248K sold.

Telemetry Investments first reported a position in ALNY in Q1 2018 and held it in 1 quarter. The position peaked at $298K in Q1 2018. 310 funds tracked by Wall St. Rank hold ALNY as of Q2 2018.

  • Telemetry Investments reported no remaining Alnylam Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Telemetry Investments sold 2,500 Alnylam Pharmaceuticals shares in Q2 2018, an estimated $248K.
  • Telemetry Investments first reported a position in Alnylam Pharmaceuticals in Q1 2018 and held it in 1 quarter.
  • Telemetry Investments's Alnylam Pharmaceuticals position peaked at $298K in Q1 2018.
  • 310 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2018.

Based on Telemetry Investments's 13F filing for Q2 2018, filed 14 Aug 2018.